Past issues are only available to subscribers. If you are not a member, click here to join.

November 2017PDF

 

Hematologic malignancies

CD22 CAR-T therapy shows results in leukemia study

A new type of CAR-T therapy that targets the protein CD22 helped achieve remission in nearly 60 percent of leukemia patients who had failed or relapsed on other treatments, according to a paper published in Nature Medicine.

 

Immunotherapy

Mount Sinai researchers develop first mathematical model for predicting patient response to immunotherapy

Researchers at the Icahn School of Medicine at Mount Sinai have created the first mathematical model that can predict how a cancer patient will benefit from certain immunotherapies, according to a study published in Nature.

 

Lung cancer

Phase III study shows Tecentriq and Avastin plus chemo reduced risk of disease progression or death in advanced lung cancer

Genentech said the phase III IMpower150 study met its co-primary endpoint of progression-free survival and demonstrated that the combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy (paclitaxel and carboplatin) provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death compared to Avastin plus chemotherapy in the first-line treatment of people with advanced non-squamous non-small cell lung cancer.

 

Breast Cancer

Novartis reports positive results from phase III trial of Kisqali for advanced or metastatic breast cancer

 

Genitourinary cancers

Clinical data for CXCR4 inhibitor, Inlyta showa 29% ORR in clear cell renal cell carcinoma

 

Brain tumors

Ziopharm announces positive updated results of Ad-RTS-hIL-12 study in brain cancer

 

NCI CTEP-Approved Trials for November

 

Regulatory actions

FDA approves adjuvant indication for Sutent in renal cell carcinoma

  
CCL Nov 2017 - Dec. 7, 2017
Issue 44 - Nov. 28, 2017
  • Caligiuri named president of City of Hope National Medical Center

    Michael Caligiuri was named physician-in-chief of City of Hope and president of City of Hope National Medical Center.

    Caligiuri recently stepped down as director of The Ohio State University Comprehensive Cancer Center and as CEO of the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

    He will join City of Hope in this newly created position next February. The appointment was announced on Nov. 28.

  • Conversation with the Cancer Letter

    Caligiuri: It was time for me to hit the refresh button on my career

    After 20 years at Ohio State University, Michael Caligiuri is moving on.

    Caligiuri was named physician-in-chief of City of Hope and president of City of Hope National Medical Center on Nov. 28. He stepped down as director of The Ohio State University Comprehensive Cancer Center and as CEO of the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute earlier this month.

  • NCI Director’s Report

    Sharpless lists initial priorities for NCI: Big Data, cell therapy, and more trials at the NIH Clinical Center

    NCI needs to focus on developing a structured approach to Big Data initiatives to ensure optimal use of the institute’s limited resources, said NCI Director Norman “Ned” Sharpless at his first joint meeting of the National Cancer Advisory Board and the Board of Scientific Advisors.

  • FDA approves Foundation Medicine’s genomic profiling test for all solid tumors; CMS proposes coverage

    FDA has approved the FoundationOne CDx, the first breakthrough-designated, next generation sequencing-based in vitro diagnostic test that can detect genetic mutations in 324 genes and two genomic signatures in any solid tumor type.

    The Centers for Medicare & Medicaid Services—at the same time—proposed coverage of the F1CDx, a laboratory-developed test sponsored by Foundation Medicine.

  • In Brief

    • FDA’s Pazdur named to Bloomberg 50 list
    • National Academies report calls for government negotiation of drug prices
    • Antonio Wolff named chair of ECOG-ACRIN Breast Cancer Committee
    • Louis Weiner to lead MedStar Georgetown Cancer Institute
    • LLS awards $5 million grant to team led by Sylvester’s Stephen Nimer
    • Ronda Henry-Tillman named to Kohn Chair in breast surgical oncology UAMS
    • NCCN, in collaboration with Pfizer, awards nine grants for quality improvement in breast cancer
    • Ronald Maier elected president of American College of Surgeons
    • Leigh Neumayer elected chair of the ACS board of regents
  • Drugs and Targets

    • FDA approves Ogivri, first biosimilar for treating breast and stomach cancers
    • Tesaro receives European approval of Zejula for recurrent ovarian cancer
    • G1 Therapeutics and AstraZeneca enter clinical trials collaboration in NSCLC
    • ITUS Corp. Moffitt enter into CRADA to develop CAR-T technology
Issue 43 - Nov. 17, 2017
  • Defining the next level for Inova

    In 2010, John Knox Singleton, the CEO of the Inova Health System, had several meetings with John Niederhuber, a surgeon and scientist who had just been replaced as NCI director.

    At the time, Niederhuber still had a lab at NIH, but was plotting the next step in his career. Singleton had been Inova’s CEO since 1984.

  • Caligiuri resigns as CEO of the James after stepping down as director of OSUCCC

    Michael Caligiuri, who over the past 14 years demonstrated virtuosity in recruitment, lobbying, and fundraising, building the third-largest cancer hospital in the U.S., has stepped down as director of The Ohio State University Comprehensive Cancer Center and as CEO of the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

  • An Appreciation

    Hail to “The Chief” Donald S. Coffey, a scientist, a mentor, a wit, dies at 85

    Donald S. Coffey, Ph.D., cancer warrior, humanist, mentor to hundreds of researchers and physicians, friend to countless people, was filled with a burning curiosity to understand the world and to know personally everyone he came in contact with.

    Everyone has the story—“I met Don at a meeting and he sat me down and he asked me to tell him my life story—and I was forever changed.”

  • In Brief

    • De la Chapelle receives lifetime achievement award from colorectal cancer group
    • Gallagher named vice president and head of Global Oncology Development at AbbVie 
    • Sylvester geneticist Shiekhattar receives NIH “Pioneer Award” 
    • WPI’s Mattson receives $1.7-million NIH award to develop molecular methods
    • LUNGevity partners with ALK Positive Patient Group to fund research
  • Drugs and Targets

    • FDA approves adjuvant indication for Sutent in renal cell carcinoma
    • FDA approves obinutuzumab for previously untreated follicular lymphoma
    • FDA approves Sprycel for pediatric patients with CML
    • FDA approves Genentech’s Hemlibra to prevent bleeding in hemophilia A
    • FDA authorized MSKCC’s tumor profiling tests